Non-Hodgkin Lymphoma | Specialty

Practicality of CAR T Therapy

January 9th 2018

The Status of CAR T in Hematologic Malignancies

January 9th 2018

Dr. Martin on Trial of Oral Azacitidine Plus R-CHOP in High Risk DLBCL

January 6th 2018

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses a trial of the combination of oral azacitidine (CC-486) and R-CHOP in diffuse large B-cell lymphoma (DLBCL).

The Future Treatment of Follicular Lymphoma

January 5th 2018

Immunotherapy in the Treatment of Follicular Lymphoma

January 5th 2018

FL: Potential for SYK/JAK Inhibitors or Azacitidine

January 5th 2018

Novel Agents in FL: Unmet Needs and Potential Uses

January 5th 2018

Follicular Lymphoma: Novel Approaches With Rituximab

January 5th 2018

Follicular Lymphoma: Optimizing Novel Agent Therapy

January 5th 2018

Third-Line Treatment for FL: PI3 Kinase Inhibitors

January 5th 2018

Choosing Second-Line Therapy for Relapsed/Refractory FL

January 5th 2018

Predicting and Analyzing Response in Follicular Lymphoma

January 5th 2018

Challenging the Role of Maintenance Therapy in FL

January 5th 2018

Upfront Therapy Strategies in Follicular Lymphoma

January 5th 2018

Follicular Lymphoma: Outcomes After Immunochemotherapy

January 5th 2018

Practical Considerations for Subcutaneous Rituximab

December 29th 2017

Subcutaneous Rituximab: A New Approach to Treating FL

December 29th 2017

Highlights from ASH 2017: Mantle Cell Lymphoma

December 23rd 2017

Investigational Treatment in Mantle Cell Lymphoma

December 23rd 2017

Future Therapy: Bruton's TKI Containing Combinations in MCL

December 23rd 2017